KALA Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect 眼科查看全文
發仔说美股2022-12-30 17:30
【美股盘前 | 药品制造商Kala续涨超6%,Wedbush予其47美元目标价】
华盛资讯12月30日消息,美股盘前,三大期指走弱,截至发稿,纳指期货跌0.61%,标普500指数期货跌0.45%,道指期货跌0.32%。
药物制造商Kala Pharmaceuticals盘前上涨6.68%,近两个交易日涨逾317%,Wedbush分析师Andreas Ar...查看全文
一周一次的见面会又来了,还是我→美股风向标。致力于追踪热门美股优质标的,挖掘更多投资机会。接下来我们来看看本周有哪些重要的标的可以关注吧! 1、Kala制药公司 $KALA 表示,FDA接受了其主要候选产品KPI-012——治疗眼睛罕见疾病的研究... 网页链接
智通财经APP获悉,专注于眼部护理的全球医疗专业公司爱尔康(ALC.US)宣布,同意从生物制药公司Kala Pharma(KALA.US)手中收购EYSUVIS(0.25%氯替泼诺混悬滴眼液)和INVELTYS(1%氯替泼诺混悬滴眼液)。 据了解,EYSUVIS是首个也是唯一一个获FD... 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-010879 Size: 5 KB 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-010880 Size: 5 KB 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-010881 Size: 6 KB 网页链接
$Kala制药(KALA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-010882 Size: 5 KB 网页链接
$Kala制药(KALA)$ 8-K Current report, items 3.03, 5.03, 5.07, 7.01, and 9.01 Accession Number: 0001558370-22-015128 Act: 34 Size: 236 KB 网页链接
$Kala制药(KALA)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-22-098939 Act: 34 Size: 774 KB 网页链接
$Kala制药(KALA)$ PRE 14A Other preliminary proxy statements Accession Number: 0001104659-22-096093 Act: 34 Size: 1 MB 网页链接
$Kala制药(KALA)$ 8-K Current report, items 3.03, 5.03, 7.01, and 9.01 Accession Number: 0001558370-22-013802 Act: 34 Size: 218 KB 网页链接
$Kala制药(KALA)$ 8-A12G Registration of securities [Section 12(g)] Accession Number: 0001558370-22-013800 Act: 34 Size: 80 KB 网页链接
$Kala制药(KALA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-22-013308 Act: 34 Size: 9 MB 网页链接